GENERAL
Piramal Pharma Acquires Additional 40.67% Stake In Yapan Bio For ₹76 Cr
Piramal Pharma Ltd has completed the acquisition of an additional 40.67% stake in Yapan Bio Pvt Ltd for ₹76 crore, taking its total holding in the Hyderabad-based company to 74%. With the completion of the transaction on August 18, Yapan Bio has become a subsidiary of Piramal Pharma. The company is a contract development and […]
CW Bureau
·
Aug 19, 2026
GENERAL
Glenmark Specialty Advances Global Phase 3 Trial For Ovarian Cancer Drug
Glenmark Pharmaceuticals Ltd, through its wholly owned subsidiary Glenmark Specialty S.A., has advanced the Phase 3 clinical development of Trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate (ADC), for the treatment of platinum-resistant ovarian cancer (PROC). India will become the first country across Glenmark’s licensed markets to initiate patient enrolment for the global Phase 3 clinical trial […]
CW Bureau
·
Jul 2, 2026
GENERAL
Shilpa Biologicals Commissions ADC Drug Substance Manufacturing Unit
Shilpa Biologicals Ltd, a material subsidiary of Shilpa Medicare Ltd, has commissioned a Good Manufacturing Practice (GMP)-compliant Antibody-Drug Conjugate (ADC) manufacturing facility designed to meet global regulatory standards. The facility is fully operational, with GMP qualification protocols currently underway, paving the way for commercial-scale operations. Integrated ADC capabilities With the commissioning of the facility, Shilpa […]
CW Bureau
·
Jun 24, 2026
